“Cell Therapy in Solid Tumors” was moderated by Li Watsek and Prakhar Agrawal. It featured Drew Deniger, VP, R&D of Alaunos Therapeutics, William Ho, CEO of IN8bio, Dr. Maden Jagasia, EVP of Iovance Biotherapeutics, Inc., and Kristi Jones, CEO of NexImmune, Inc.

• Alaunos is focused on attacking solid tumors with novel TCR-T cell therapies. It discussed its non-viral sleeping beauty platform, noting it’s the ideal fit for cell therapies because it’s rapid, cost-effective, and flexible. Alaunos highlighted the rationale for going after hotspot mutations as well as specifics of its ongoing phase 1/2 TCRT library trial.

• IN8BIO is focused on creating autologous, allogenic, and genetically modified gamma-delta T-cell therapies using its DeltEx platform. It spoke about INB-200’s encouraging survival and toxicity profile in glioblastoma patients, as well as expectations for the coming months.

• Iovance spoke about the unique nature of tumor-infiltrating lymphocytes (TILs), and their advantages over T-cell or NK-cell therapies. It also touched upon its positive data from lifileucel in melanoma, as well as plans to scale up manufacturing to prepare for its launch.

• NexImmune highlighted its adoptive cell therapy approach uses synthetic nanoparticles to deliver instructions (multiple antigens) to natural T cells that can potentially provide better precision, persistency and potency compared to other cell therapy approaches. NexImmune initial focus in solid tumors is on targeting HPV-related cancer with phase 1 trial to begin this year. NexImmune also noted its off-the-shelf injectable therapeutic that could have broad applications in oncology and autoimmune diseases.

#Cantorconferenceseries #Oncology #Hematology #Hemeonc #Cantorfitzgerald #Cantorhealthcare